Want to see ES:ATRY full AI Analyst Report?
Atrys Health SA (ATRY) AI Stock Analysis
Top Page
Atrys Health SA
(BME:ATRY)
The score is driven primarily by weak financial performance (persistent losses, negative free cash flow, and deterioration in 2025) and a negative P/E that reflects ongoing unprofitability. Technicals provide only limited support, showing a short-term improvement but a broader downtrend versus longer-term moving averages.
Atrys Health SA (ATRY) vs. iShares MSCI Spain ETF (EWP)
- Market Cap
- EUR 198.30M
- Dividend Yield
- ―
- Average Volume (3M)
- 34.48K
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- 0.26
- Revenue Growth
- -53.44%
- EPS Growth
- -296.14%
- Country
- Spain
- Employees
- 763
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Atrys Health SA Business Overview & Revenue Model
Company Description
Atrys Health, S.A., a biomedical enterprise founded in 2007 and based in Madrid, Spain, specializes in providing a range of diagnostic services and medical treatments. Its diagnostic portfolio encompasses areas like pathology, hematology, molecular p...
How the Company Makes Money
Atrys Health makes money primarily by providing healthcare services and being paid for those services, with revenues largely tied to (1) oncology-related clinical activity—most notably radiation oncology treatments delivered through its network of ce...
Atrys Health SA Financial Statement Overview
Summary
Underlying financial quality is weak. The income statement shows persistent operating losses and a sharp revenue contraction in 2025, while cash flow is consistently negative with worsening free cash flow in 2025. The balance sheet is somewhat supportive with manageable leverage in prior years, but equity has declined and losses continue to erode shareholder value.
Income Statement
34NegativeBalance Sheet
52NeutralCash Flow
29Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.48M | 141.01M | 212.74M | 201.57M | 158.37M | 121.01M |
| Gross Profit | 38.51M | 61.35M | 145.38M | 141.77M | 24.20M | 100.89M |
| EBITDA | -16.60M | -9.96M | 19.07M | 31.91M | 16.63M | 5.87M |
| Net Income | -97.39M | -100.30M | -31.77M | -45.59M | -23.15M | -23.20M |
Balance Sheet | ||||||
| Total Assets | 315.60M | 494.04M | 584.19M | 629.00M | 705.28M | 565.63M |
| Cash, Cash Equivalents and Short-Term Investments | 12.49M | 17.76M | 29.29M | 42.18M | 35.84M | 41.70M |
| Total Debt | 118.42M | 257.87M | 166.13M | 254.00M | 241.22M | 154.95M |
| Total Liabilities | 168.11M | 342.08M | 330.95M | 339.12M | 367.71M | 291.65M |
| Stockholders Equity | 147.43M | 151.86M | 253.10M | 289.87M | 337.63M | 274.03M |
Cash Flow | ||||||
| Free Cash Flow | -14.73M | -14.08M | -10.14M | -547.00K | -30.59M | -3.87M |
| Operating Cash Flow | -4.73M | -1.56M | 3.00M | 5.70M | -15.43M | 4.69M |
| Investing Cash Flow | 134.07M | -12.59M | -12.95M | 395.00K | -80.59M | -2.45M |
| Financing Cash Flow | -126.29M | 11.28M | -11.51M | 8.19M | 94.77M | 14.08M |
Atrys Health SA Peers Comparison
Overall Rating
ES:PHM73Outperform
ES:PRM62Neutral
ES:ORY45Neutral- ES:ATRY43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ES:PHM | 73Outperform | EUR 1.20B | 20.69 | 23.64% | 1.48% | 15.52% | 34.76% |
| ES:PRM | 62Neutral | EUR 210.17M | 16.35 | 9.47% | 4.06% | 4.20% | -10.44% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| ES:ORY | 45Neutral | EUR 198.99M | -77.82 | -2.23% | ― | ― | 53.50% |
| ES:ATRY | 43Neutral | EUR 198.30M | -2.03 | -65.08% | ― | -53.44% | -296.14% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ES:ATRY | Atrys Health SA | 2.61 | -0.63 | -19.44% | |
| ES:ORY | Oryzon Genomics | 2.43 | -1.07 | -30.63% | |
| ES:PHM | Pharma Mar SA | 67.50 | -4.57 | -6.34% | |
| ES:IKM | 1nKemia IUCT Group SA | 0.31 | 0.00 | 0.00% | |
| ES:PRM | PRIM, S.A. | 12.40 | -1.06 | -7.85% | |
| ES:LAB | Labiana Health SA | 5.20 | 0.88 | 20.48% |
Atrys Health SA Corporate Events
Atrys Health Reports Strong Quorum and Approved Resolutions at 2026 Shareholders’ Meeting
Atrys Health disclosed the results of its Ordinary General Shareholders’ Meeting held on 18 June 2026 in Madrid, where shareholders approved all resolutions presented by the board. The meeting was convened in compliance with EU and Spanish secu...
Atrys boosts profitability, slashes debt and expands oncology footprint in Q1 2026
Atrys Health reported first-quarter 2026 revenue of 37.5 million euros, up 6.3% year-on-year, while EBITDA rose 15.4% to 4.1 million, driven by strong gains in Oncology, Nuclear Medicine and Diagnostic Imaging, particularly in Mexico and Portugal. Op...
Atrys Health Boosts Q1 Profitability and Slashes Debt as International Oncology Business Accelerates
Atrys Health posted first-quarter 2026 revenue of 37.5 million euros, up 6.3% year on year, while EBITDA rose 15.4% to 4.1 million, driven by strong gains in Oncology, Nuclear Medicine and Diagnostic Imaging, particularly in Mexico and Portugal. The...
Atrys Health Lifts Q1 2026 Earnings, Cuts Debt and Deepens Oncology Focus
Atrys Health SA reported solid first-quarter 2026 results, with revenue up 6.3% and EBITDA rising 15.4% year on year, driven by strong performances in Portugal, Latin America and especially Mexico, as well as double-digit growth in radiology and radi...
Atrys Health Names Veteran Finance Executive Alberto Iriondo as New CFO to Drive Next Growth Phase
Atrys Health has appointed Alberto Iriondo as its new Chief Financial Officer and member of the Executive Committee, reinforcing its leadership team at a time of balance sheet strengthening, debt reduction and sharper focus on core strategic business...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026